Search clinical trials for: complete blood count, CD3 , CD4 , CD8 , CD16 , CD56 , IFN-γ.

Total 30 results

Assiut University

Not yet recruiting

Immune Markers in Pediatric ITP on Second Line Therapy

ITP - Immune Thrombocytopenia
Assiut University

Unknown

Prognostic Value of CD Markers in Immune Thrombocytopenic Purpura

Immune Thrombocytopenia
Kazakhstan's Medical University "KSPH"
Vyacheslav Notanovich Lokshin; Nurgalieva Zhanar Zhenisovna; Manzhuova Lyazzat... and other collaborators

Completed

Health Status of Children Born After Assisted Reproductive Technologies

Child Development | Health Status | Children Born After Assisted Reproductive Technologies

Kazakhstan
University Hospital, Basel, Switzerland

Completed

NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)

Lymphoma | Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Neuroblastoma | Rhabdomyosarcoma

Switzerland, Germany
Masonic Cancer Center, University of Minnesota
Miltenyi Biomedicine GmbH

Withdrawn

CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission

Acute Myelogenous Leukemia

United States
Stephan Grupp MD PhD

Recruiting

Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

Systemic Lupus Erythematosus | Systemic Sclerosis

United States
Biotech Pharmaceutical Co., Ltd.

Terminated

Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis

Psoriasis

China
Vanderbilt University
National Institutes of Health (NIH)

Completed

Optimizing Integrated PMTCT Services in Rural North-Central Nigeria

HIV | Suspected Damage to Fetus From Viral Disease in the Mother

Nigeria, Niger
Technische Universität Dresden
German Research Foundation

Terminated

Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML (HINKL)

Acute Myeloid Leukemia

Germany
University of Salamanca

Recruiting

Efficacy of Complex Decongestive Therapy (CDT) in Patients With Venous Insufficiency: a Experimental Study (CDT)

Lymphatic Edema | Cellulitis of Leg | Vein Disease

Spain
Sohag University

Recruiting

A Study of Acute Kidney Injury in Children at Sohag University Hospital

Acute Kidney Injury

Egypt
Asan Medical Center

Unknown

Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic Anemia

Acquired Aplastic Anemia

Korea, Republic of
King's College Hospital NHS Trust

Unknown

Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy (PRO-DLI)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United Kingdom
University Hospital Inselspital, Berne

Completed

PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma (PAV)

Myeloma

Switzerland
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Institute of Allergy and Infectious...

Terminated

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Myelodysplastic Syndromes | Leukemia | Graft Versus Host Disease

United States
Roswell Park Cancer Institute
Celgene

Active, not recruiting

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Plasma Cell Myeloma | Partial Response of Multiple Myeloma or Plasma Cell Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Richter Syndrome | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory Transformed Chronic Lymphocytic Leukemia

United States
Fred Hutchinson Cancer Center
Nektar Therapeutics

Recruiting

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recurrent Grade 3b Follicular Lymphoma | Refractory Grade 3b Follicular... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Smoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple Myeloma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Erythroid Leukemia | Acute Megakaryoblastic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blast Phase Chronic Myelogenous Leukemia,... and other conditions

United States
David Bond, MD

Recruiting

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1

United States, Puerto Rico, Israel
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Philadelphia Chromosome Negative

United States
Monica Levy Andersen

Completed

Mother-caregivers of Children With Duchenne Muscular Dystrophy (DMDK)

Other Diseases or Conditions

Brazil
National Cancer Institute (NCI)

Not yet recruiting

A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)

B Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)

Suspended

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Down Syndrome | Recurrent B Acute Lymphoblastic Leukemia

United States, Canada, Puerto Rico, Australia
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States, Canada, Israel, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia

United States, Canada, Puerto Rico, Australia, New Zealand
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

B Acute Lymphoblastic Leukemia | Acute Leukemia of Ambiguous Lineage
National Cancer Institute (NCI)

Recruiting

A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia

Down Syndrome | B Acute Lymphoblastic Leukemia | B Lymphoblastic Lymphoma

United States, Canada, Puerto Rico, Australia, New Zealand

Search clinical trials for: complete blood count, CD3 , CD4 , CD8 , CD16 , CD56 , IFN-γ.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations